Mesenchymal stem cell therapy - Medipost

Drug Profile

Mesenchymal stem cell therapy - Medipost

Alternative Names: Bonestem; Heartstem; Promostem

Latest Information Update: 16 Sep 2015

Price : $50

At a glance

  • Originator Medipost
  • Class Antineoplastics; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Bone disorders; Myocardial infarction
  • Discontinued Glioma; Graft-versus-host disease

Most Recent Events

  • 17 Aug 2012 Medipost's Mesenchymal stem cell therapy is available for licensing. http://www.medi-post.co.kr
  • 12 Jun 2012 No development reported - Preclinical for Bone disorders in South Korea (Parenteral)
  • 12 Jun 2012 No development reported - Preclinical for Myocardial infarction in South Korea (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top